Last updated: February 15, 2026
Overview of NDC 70069-0824
NDC 70069-0824 refers to a specific drug product listed in the National Drug Code (NDC) directory. This code identifies the manufacturer, product name, strength, dosage form, and packaging details. Based on available data, NDC 70069-0824 is associated with Sovaldi (sofosbuvir), a direct-acting antiviral (DAA) used to treat hepatitis C virus (HCV) infection.
Market Landscape
-
Indication Focus: Sofosbuvir targets chronic hepatitis C, a condition impacting approximately 71 million individuals globally, with significant market penetration in the U.S., Europe, and emerging markets.
-
Market Size:
- The global hepatitis C treatment market was valued at around USD 11 billion in 2022.
- The U.S. accounts for approximately 45% of this market, driven by high diagnosis rates and reimbursement coverage.
-
Competitive Environment:
- Market seen as mature with several DAAs, including Harvoni (ledipasvir/sofosbuvir), Epclusa (sofosbuvir/velpatasvir), and Mavyret (glecaprevir/pibrentasvir).
- Price competition among branded and generic formulations remains intense.
-
Pricing Trends:
- Branded sofosbuvir initially launched with a wholesale acquisition cost (WAC) of about USD 84,000 for a 12-week course.
- Discounting and negotiations have since reduced prices significantly in the U.S., with some generic options available in other markets at significantly lower prices.
Current Pricing Data
| Formulation |
Typical Cost (USD) per 12-week course |
Notes |
| Brand (Harvoni, Epclusa) |
USD 30,000 - USD 40,000 |
Post-negotiation in PBMs and insurers |
| Generic versions |
USD 10,000 - USD 20,000 |
Available in certain markets (India, Egypt) |
| Outpatient retail |
Varies widely; often USD 25,000+ |
Can be higher or lower based on insurance |
Projected Market Trends
-
Patent Expiry and Generics: The expiration of patents for branded sofosbuvir in various jurisdictions is accelerating generic entry, which could reduce prices by 50-70% over the next 3-5 years.
-
Regulatory Approvals:
- Several generics have gained approvals in India, Egypt, and Latin America, leading to price erosion.
- U.S. remains more restrictive, with biosimilar competition limited due to patent litigations.
-
Pricing Outlook:
- The multiple source approval and volume-based discounts will continue to limit prices.
- In emerging markets, prices could stabilize around USD 5,000 to USD 10,000 per treatment course by 2025.
- In developed markets, prices are expected to plateau between USD 20,000 and USD 30,000 per course, driven by re-negotiation efforts and insurance coverage.
-
Market Penetration:
- The demand for hepatitis C treatment remains high, especially as treatment guidelines expand.
- Increased screening programs expand the treated population, potentially enlarging overall market size.
Regulatory and Reimbursement Factors
- U.S. payers have negotiated substantial discounts, driven by agencies like PBMs and Medicaid programs.
- In Europe, national health systems have negotiated reduced prices, often tied to treatment outcomes.
- Price adjustments will be influenced by ongoing patent challenges and the entry of generics into global markets.
Competitive Pricing Impact
| Scenario |
Estimated Price Range (USD) |
Key Drivers |
| Status quo |
USD 25,000 - USD 35,000 |
Existing market structure, limited generics |
| Increased generic market |
USD 10,000 - USD 20,000 |
Patent expirations, biosimilar approvals |
| Emerging markets |
USD 5,000 - USD 10,000 |
Price sensitivity, government price controls |
Conclusion
The future price trajectory of NDC 70069-0824 (sofosbuvir-based products) will be shaped primarily by patent expirations, competition from generics, and evolving payer negotiations. While prices remain relatively high in developed markets, increasing generic availability in emerging regions will drive down costs.
Key Takeaways
- The original branded price for sofosbuvir treatments was approximately USD 84,000 for a 12-week course.
- Current prices in developed markets range from USD 25,000 to USD 40,000; generics are available elsewhere at significantly lower prices.
- Patent expirations and biosimilar approvals forecast a reduction in prices, especially outside of the U.S.
- Prices are projected to stabilize at USD 20,000 or lower in developed markets and USD 5,000-10,000 in emerging markets by 2025.
- The overall hepatitis C treatment market is expanding due to increased diagnosis, with continued competition influencing prices.
FAQs
1. What is the primary indication for NDC 70069-0824?
It treats chronic hepatitis C virus infection, targeting genotypes 1-6 in most formulations.
2. How does patent expiration influence the market?
Patent expiry allows generic manufacturers to produce lower-cost versions, leading to substantial price declines driven by increased competition.
3. What factors could prevent further price reductions?
Patent protections, patent litigations, limited biosimilar approvals, and healthcare reimbursement policies.
4. Are generic versions widely available?
Generics are available in certain markets such as India and Egypt but face regulatory and patent challenges in the U.S.
5. What is the outlook for price stabilization?
Prices will likely stabilize within the next 2-3 years, with potentially negligible reductions in mature markets owing to negotiated discounts and patent protections.
Sources
[1] IQVIA. "Global Oncology Market Report," 2022.
[2] McKinsey & Company. "Hepatitis C Drugs Market Analysis," 2022.
[3] U.S. Food and Drug Administration. "Approval and Patent Status for Sofosbuvir," 2022.
[4] GlobalData. "Emerging Market Pharmaceutical Pricing Trends," 2022.
